- Alita’s latest Cohealyx study has demonstrated accelerated time to skin grafting, with the full dataset expected later in CY26.
- Demonstrated statistical superiority versus a literature-derived benchmark.
- Investigators reported 90% satisfaction at time of grafting.
Leading therapeutic acute wound care company Avita Medical (ASX:AVH) has unveiled a significant reduction in mean time to skin grafting in positive interim results from its Cohealyx-I multi-centre study.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The results have demonstrated a reduction of nearly 20 days for patients with full-thickness wounds. Avita’s CY26 study has also demonstrated statistical superiority versus a literature-derived benchmark, which the biotech company says was based on the lower bound of the 95% confidence interval.
The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients.
An interim analysis of 40 patients showed a median time to grafting of 11 days. Grafting was achieved as early as five days, with 25% grafted within seven days and 72% grafted within 14 days.
Professor of plastic surgery Derek Bell, MD, and Kessler Burn, the director at the University of Rochester Medical Centre, together noted that investigators reported 90% satisfaction at the time of grafting.
“Preparing the wound bed efficiently remains one of the key challenges in managing full-thickness wounds,” Professor Bell said.
“These interim results show that Cohealyx supports vascularisation and enables earlier grafting, which is central to improving patient outcomes. Importantly, these results were achieved across a myriad of diverse and complex wounds.”
Cary Vance, Avita’s interim CEO, said the data has strengthened the company’s belief that Cohealyx can set a new benchmark in wound bed preparation.
“The meaningful reduction in time to grafting and high investigator satisfaction highlight its potential as a differentiated solution with the ability to drive broader adoption as we work to improve each stage of the wound healing pathway,” he said.
Cohealyx-I is a prospective, single-arm, post-market, multi-centre study evaluating the safety of Cohealyx in patients with full-thickness wounds following surgical excision. The primary endpoint is time to autografting.
Patients underwent a staged surgical approach, with Cohealyx applied to the wound bed following excision and autografting performed once adequate vascularisation was achieved. Secondary endpoints include graft take, wound healing, and safety outcomes. Patients are followed for approximately six months post-grafting to assess durability of outcomes and monitor adverse events.
AVH will open at $1.35 today.
Join the discussion: See what HotCopper users are saying about Avita Medical Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.